The Korean biopharmaceutical industry is successfully signing license agreements of drugs for autoimmune diseases. HK inno. N, IMBiologics, and Y-Biologics have signed license agreements for their jointly developed novel drug candidates. AprilBio has also signed a license agreement for a novel drug candidate that has shown efficacy in a phase 1 trial.

This is not the first time Korean companies have successfully entered into license agreements for novel drugs for autoimmune diseases. LG Chem, Voronoi, Hanall Biopharma, and Daewoong have also completed technology transfers overseas. Even after out-licensing, these treatments have demonstrated efficacy, confirming South Korea’s R&D capacity.